Inpatient and Outpatient Orderable
OnkoSight Myeloid Seq
Build info
Synonyms
|
- ONKOSIGHT NGS MYELOID MALIGNANCIES PANEL
- ONKOMYELO
- LAB10522
|
Short Name
|
Onkosight NGS Myeloid Malignancies
|
Procedure Master Number
|
LAB10522
|
Procedure ID
|
111548
|
Clinical Info
|
Tumor sequencing by NGS detecting mutations in 50 genes associated with myeloid malignancies.
Mutations often have prognostic significance, may confer resistance to FDA approved
therapies, or may qualify patients for late-stage clinical trials.
|
Specimen Sources
|
Blood, Arterial
Blood, Capillary
Blood, Central Line
Blood, Venous
Bone Marrow
Bone Marrow Aspirate
|
Specimen Types
|
Aspirate
Blood
Bone Marrow
|
Container
|
Sterile
|
Collection Instructions
|
Peripheral Blood - Lavender Top or Green Top Tube
Bone Marrow - Green Top
Eppendorf tube, Unstained Slide, Formalin-fixed, Paraffin-embedded Tissue
Decalcified specimens are not recommended for NGS testing
** Note: Please indicate specimen type on tube **
Test Code TL95
|
Transport Instructions
|
Room Temperature
|
Specimen Stability
|
7 Days Refrigerated Blood samples older than 7 days can still be shipped, they will be tested if the yield and quality of DNA permit.
|
Methodology
|
Genotyping by Next Generation Sequencing
Includes:
Genes ABL1; ANKRD26; ASXL1; ATRX; BCOR; BCORL1; BRAF
CALR; CBL; CCND2; CDKN2; CEBPA: CSF3R; CUX1
DDX41: DNMT3A: ETNK1: ETV6: EZH2: FBXW7; FLT3
GATA2; HRAS; IDH1; JAK2; KDM6A; KIT; KMT2A; KRAS
MAP2K1; MPL; MYD88; NF1; NPM1; NRAS; PDGFRA
PHF6; PTEN; PTPN11; RUNX1; SETBP1; SF3B1; SRSF2
STAG2; TET2; TP53; U2AF1; WT1; ZRSR2
|
Days Performed
|
TAT: 10 - 12 Days
|
Performing Laboratory
|
Genpath BioReference
|
CPT
|
81450
81451
|
PDM
|
1659893
|
Only Orderable at Locations:
|
Orderable Everywhere
|
Results
|
| Component Name |
Base Name |
Common Name |
External Name |
| ONKOSIGHT MYELOID SEQUENCE |
ONKOMYSEQ |
ONKO MYELO SEQ |
Onkosight Myeloid Sequence |
| MYE THERAPEUTIC AND PROGNOSTIC ASSOCIATIONS |
MYEPROG |
MYE THERAPEUTIC AND PROGNOSTIC ASSOCIATIONS |
Mye Therapeutic And Prognostic Associations |
| MYE INTERPRETATION SUMMARY |
MYEINTERP |
MYE INTERPRETATION SUMMARY |
Mye Interpretation Summary |
| MYE DETAILED GENETIC INTERPRETATION 1 |
MYEGENINT1 |
MYE DETAILED GENETIC INTERPRETATION 1 |
Mye Detailed Genetic Interpretation 1 |
| MYE DETAILED GENETIC INTERPRETATION 2 |
MYEGENINT2 |
MYE DETAILED GENETIC INTERPRETATION 2 |
Mye Detailed Genetic Interpretation 2 |
| MYE CLINICAL TRIALS 1 |
MYECT1 |
MYE CLINICAL TRIALS 1 |
Mye Clinical Trials 1 |
| MYE CLINICAL TRIALS 2 |
MYECT2 |
MYE CLINICAL TRIALS 2 |
Mye Clinical Trials 2 |
| MYE TECHNICAL SUMMARY |
MYETECH |
MYE TECHNICAL SUMMARY |
Mye Technical Summary |
| MYE METHODS |
MYEMETHOD |
MYE METHODS |
Mye Methods |
| MYE REFERENCES 1 |
MYEREF1 |
MYE REFERENCES 1 |
Mye References 1 |
| MYE REFERENCES 2 |
MYEREF2 |
MYE REFERENCES 2 |
Mye References 2 |
| MYE REPORT FOOTER |
MYEREPORT |
MYE REPORT FOOTER |
Mye Report Footer |
| MYE ADDENDUM |
MYE |
MYE ADDENDUM |
Mye Addendum |
| MYE ALLELE FREQUENCIES |
MYE |
MYE ALLELE FREQUENCIES |
Mye Allele Frequencies |
|
